Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2ATZB)

• Drug Name: Deoxynojirimycin Drug Info
• Synonyms: 1-DEOXYNOJIRIMYCIN; 19130-96-2; DUVOGLUSTAT; deoxynojirimycin; Moranoline; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; 1,5-Deoxy-1,5-imino-D-mannitol; Moranolin; UNII-FZ56898FLE; D-1-deoxynojirimycin; 1,5-Dideoxy-1,5-imino-D-glucitol; CHEMBL307429; C6H13NO4; FZ56898FLE; CHEBI:44369; 1-Deoxy-Nojirimycin; 5-Amino-1,5-dideoxy-D-glucopyranose; DNJ; AK151410; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R,3R,4R,5S)-; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-

Indication

Disease Entry	ICD 11	Status	REF
Pompe disease	5C51.3	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 29435
  ChEBI ID: CHEBI:44369
  CAS Number: CAS 19130-96-2
  TTD Drug ID: DM2ATZB

Molecule-Related Drug Atlas

Drug(s) Targeting Lysosomal alpha-glucosidase (GAA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avalglucosidase alfa	DMPW5UF	Pompe disease	5C51.3	Approved	[4]
BMN-701	DM94Y6O	Pompe disease	5C51.3	Phase 3	[5]
AT845	DMZJIIB	Pompe disease	5C51.3	Phase 2	[6]
SALACINOL	DMVKQT8	N. A.	N. A.	Phase 1/2	[7]
SPK-3006	DMK9DG5	Pompe disease	5C51.3	Phase 1/2	[8]
GZ402666	DMGO6M1	Pompe disease	5C51.3	Phase 1	[9]
5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one	DMAJWLD	Pompe disease	5C51.3	Preclinical	[10]
Alpha-Homonojirimycin	DMT17H0	Discovery agent	N.A.	Investigative	[3]
7-O-b-D-Glucopyranosyl-a-homonojirimycin	DM8IY3D	Discovery agent	N.A.	Investigative	[3]
VALIOLAMINE	DM2VQN5	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[11]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[12]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[13]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[14]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[15]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[16]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[16]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[16]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[17]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[17]

Drug(s) Targeting Intestinal maltase-glucoamylase (MGAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voglibose	DMUBP9O	Diabetic complication	5A2Y	Approved	[18]
Acarbose	DMRM3AW	Diabetic complication	5A2Y	Approved	[19]
Miglitol	DMXBQAM	Diabetic complication	5A2Y	Approved	[20]
Rh-alphaglucosidase	DMNF0G8	Pompe disease	5C51.3	Approved	[21]
Alpha-glucosidase	DM2RTGP	Muscle disease	FB3Z	Phase 3	[22]
PAZ-320	DMU0812	Type-2 diabetes	5A11	Phase 2	[23]
SC-49483	DM180VX	Acquired immune deficiency syndrome	1C62.3	Phase 2	[24]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[14]
SALACINOL	DMVKQT8	N. A.	N. A.	Phase 1/2	[25]
Celgosivir	DMD1V7I	Dengue fever	1D2Z	Phase 1/2	[26]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Inhibitor	[2]
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Inhibitor	[2]
Lysosomal alpha-glucosidase (GAA)	TTLPC70	LYAG_HUMAN	Inhibitor	[3]

References

• [1] The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat. 2009 Dec;30(12):1683-92.
• [2] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [3] In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6.
• [4] ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health.
• [5] Clinical pipeline report, company report or official report of BioMarin Pharma.
• [6] Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity. EMBO Mol Med. 2022 Jan 11;14(1):e13968.
• [7] Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4.
• [8] Clinical pipeline report, company report or official report of Spark Therapeutics
• [9] ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health.
• [10] 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2. N.A.. N.A.
• [11] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [12] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [13] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [14] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [15] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [16] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [17] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [18] Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
• [19] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [20] Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
• [21] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [22] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
• [23] Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
• [24] Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
• [25] Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
• [26] Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70.